{"id":"https://openalex.org/W4362481361","doi":"https://doi.org/10.1158/2159-8290.22531688","title":"Supplementary Figure S3 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","display_name":"Supplementary Figure S3 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362481361","doi":"https://doi.org/10.1158/2159-8290.22531688"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.22531688","doi":"https://doi.org/10.1158/2159-8290.22531688","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531688","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.22531688","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040149772","display_name":"Nicole R. Infarinato","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole R. Infarinato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103048363","display_name":"Jin H. Park","orcid":"https://orcid.org/0000-0001-7017-4979","observed_orcids":["https://orcid.org/0000-0001-7017-4979"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin H. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053226567","display_name":"Kateryna Krytska","orcid":"https://orcid.org/0009-0009-8402-8687","observed_orcids":["https://orcid.org/0009-0009-8402-8687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kateryna Krytska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019240347","display_name":"Hannah T. Ryles","orcid":"https://orcid.org/0000-0001-5126-9075","observed_orcids":["https://orcid.org/0000-0001-5126-9075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hannah T. Ryles","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102864493","display_name":"Renata Sano","orcid":"https://orcid.org/0000-0001-9630-3388","observed_orcids":["https://orcid.org/0000-0001-9630-3388"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Renata Sano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109498052","display_name":"Katherine M. Szigety","orcid":"https://orcid.org/0000-0001-9754-6381","observed_orcids":["https://orcid.org/0000-0001-9754-6381"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine M. Szigety","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017202683","display_name":"Yimei Li","orcid":"https://orcid.org/0000-0001-9067-6992","observed_orcids":["https://orcid.org/0000-0001-9067-6992","https://orcid.org/0000-0002-7046-4316"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yimei Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023840148","display_name":"Helen Y. Zou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helen Y. Zou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072732582","display_name":"Nathan V. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan V. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004738391","display_name":"Tod Smeal","orcid":"https://orcid.org/0009-0000-0320-7451","observed_orcids":["https://orcid.org/0009-0000-0320-7451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tod Smeal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073959537","display_name":"Mark A. Lemmon","orcid":"https://orcid.org/0000-0002-3379-5319","observed_orcids":["https://orcid.org/0000-0002-3379-5319"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark A. Lemmon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5030496565","display_name":"Ya\u00ebl P. Moss\u00e9","orcid":"https://orcid.org/0000-0002-3463-0399","observed_orcids":["https://orcid.org/0000-0002-3463-0399"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yael P. Moss\u00e9","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9262999892234802,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9262999892234802,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.062199998646974564,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.8989999890327454},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.7710000276565552},{"id":"https://openalex.org/keywords/ros1-inhibitors","display_name":"ROS1 inhibitors","score":0.8859999775886536},{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.6449999809265137},{"id":"https://openalex.org/keywords/in-vivo-efficacy","display_name":"in vivo efficacy","score":0.6320000290870667},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7599999904632568},{"id":"https://openalex.org/keywords/sh-sy5y-cells","display_name":"SH-SY5Y cells","score":0.8519999980926514}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9890127182006836},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.5602942109107971},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.5259756445884705},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.4771530032157898},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47172442078590393},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4541047513484955},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39839044213294983},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3763291835784912},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3667968213558197},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23650005459785461},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.08178684115409851},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.06882837414741516},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.06552460789680481},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.05430322885513306},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.051539838314056396},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.043010205030441284},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2159-8290.22531688","doi":"https://doi.org/10.1158/2159-8290.22531688","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531688","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.22531688","doi":"https://doi.org/10.1158/2159-8290.22531688","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531688","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2103600998","https://openalex.org/W4362512049","https://openalex.org/W2564097003","https://openalex.org/W2462717932","https://openalex.org/W2337713490","https://openalex.org/W2566076571","https://openalex.org/W2281758936","https://openalex.org/W2052546787","https://openalex.org/W1505421350","https://openalex.org/W1983845822"],"abstract_inverted_index":{"In":[0],"vivo":[1],"efficacy":[2],"studies":[3],"comparing":[4],"PF-06463922":[5],"treatment":[6,21],"at":[7,22],"10":[8],"mg/kg/day":[9,15],"(5":[10],"mg/kg":[11,17,24],"BID)":[12,18],"and":[13,30],"3":[14],"(1.5":[16],"with":[19],"crizotinib":[20],"100":[23],"QD":[25],"in:":[26],"A,":[27],"Felix-PDX":[28],"xenografts":[29],"B,":[31],"SH-SY5Y":[32],"xenografts.":[33]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}